

(PROGRAM)

VACCINES SUMMIT BOSTON 2023

 www.biogatesc.com/events/va-cc-in-e/

 Boston Marriott Newton Hotel, Newton, MA, USA

 +91 7995794446

 priyanka.m@bsc.events

ADVISORY BOARD MEMBERS




LUIS RÍOS NOGALES GARCÉS

EXECUTIVE VP & CDO
ILIAD BIOTECHNOLOGIES, USA



SABINE HAUCK

EVP CORPORATE DEVELOPMENT
LEUKOCARE AG, GERMANY



DON J. DIAMOND

PROFESSOR
DEPARTMENT OF HEMATOLOGY &
HEMATOPOIETIC CELL TRANSPLANTATION
CITY OF HOPE, USA



WILLIAM R. JACOBS JR.

LEO & JULIA FORCHHEIMER CHAIR
MICROBIOLOGY & IMMUNOLOGY
ALBERT EINSTEIN COLLEGE OF MEDICINE, USA

ORGANIZING COMMITTEE MEMBERS



SACHIN SRAVAN

FOUNDER & CEO
BIOGATE SCIENTIFIC CENTER



PRIYANKA M

PROJECT DIRECTOR - CONFERENCES
BIOGATE SCIENTIFIC CENTER



DEEP SAPARIA

EVENT CO-ORDINATOR
BIOGATE SCIENTIFIC CENTER

WELCOME MESSAGE




I want to personally welcome all of the delegates and speakers to the hub, as fellow Bostonians refer to this vibrant and pulsating city. This excellent locale for a conference brings together the very best talent in the vaccine field. While the conference site might be in Waltham, everything in the metro area is influenced by the dynamic commercial and academic environment in the hub locale. We have assembled a topnotch group of speakers and advisors to guide the content and direction of this meeting. The choice of topics spans the gamut of cutting edge science, commercial development, and clinical application of vaccines for a whole range of diseases in the global sense. Diseases of the developing world, the tropical climates, Africa and the middle east, and the western world are all covered by individual presentations by noted authorities in each of these disciplines. The meeting will cover both delivery mechanisms as well as individual vaccine examples for major disease groups plaguing our planet. Speakers come from national health agencies from Europe and the USA, large pharma represented by some of the most prestigious names, small biotechs and startups, and faculty from European and American academia. One could not ask for a more diverse group of speakers who will enlighten us on a range of topics than span the vaccine universe. I encourage anyone who is devoted to this discipline and its many allied academic and commercial applications to register to participate as this will be the highlight of the many conferences that will bombard you to attend. This is a “not to be missed” gathering that will enrich all of us, so when we return to our workplaces, we will have learned something new and cutting edge to incorporate into our own work and discoveries.



DON J. DIAMOND

*PROFESSOR
DEPARTMENT OF HEMATOLOGY
& HEMATOPOIETIC CELL
TRANSPLANTATION
CITY OF HOPE, USA*



It is my great pleasure to welcome all participants to the Vaccine Summit Boston 2023. I am excited to meet colleagues from the vaccine world again on-site at this vibrant biotech community in Massachusetts. After a lean period, distinguished presenters from the USA and Europe will eventually regather in Boston to share their knowledge and experience with the vaccine community. An opportunity, that provides scientific insights combined with networking opportunities across all areas. It is this scientific exchange that helps us to develop and excel in our field. With the booster of recent years, the vaccine field emerged into new areas. The Vaccine Summit Boston 2023 will present new applications of the RNA vaccine technology for prophylactic vaccines. We will also hear how vaccines can benefit from cell therapies. I am particularly excited that this conference will also delve into therapeutic vaccination concepts, aiming to treat infectious diseases or cancer. I am looking forward to fruitful interactions among participants and to an inspiring conference.



SABINE HAUCK


*EXECUTIVE VICE-PRESIDENT
CORPORATE DEVELOPMENT
LEUKOCARE AG, GERMANY*

SUPPORTERS

GOLD SPONSOR



SILVER SPONSOR



BRONZE SPONSOR



COLLABORATOR



SCHOLARLY SERVICES PARTNER



FOR SPONSORSHIP AND EXHIBITION QUERIES, PLEASE CONTACT:

SACHIN SRAVAN

Email: sachin@bsc.events

FOR SPEAKING OPPORTUNITIES AND DELEGATE SERVICES, PLEASE CONTACT:

PRIYANKA M

Email: priyanka.m@bsc.events

TARGET AUDIENCE

- C-LEVEL EXECUTIVES
- SENIOR SCIENTISTS
- DECISION MAKERS
- PRESIDENTS, VPS & SVPS
- DRUG DEVELOPERS
- ACADEMICIANS
- MANUFACTURERS
- RESEARCHERS & DEVELOPERS
- DIRECTORS
- HEALTHCARE PROFESSIONALS
- PRODUCT DEVELOPERS
- REGULATORY SPECIALISTS
- PRINCIPAL INVESTIGATORS
- CONSULTANTS

SESSION TRACKS

- NOVEL LIVE ATTENUATED VACCINES
- CANCER VACCINES
- HIV VACCINE
- COVID-19 VACCINE R&D
- INFLUENZA & RESPIRATORY
- BACTERIAL, TB & MALARIAL VACCINES
- EMERGING & RE-EMERGING DISEASES
- BIOPROCESSING & MANUFACTURING
- CLINICAL TRIALS
- VACCINES SAFETY & EFFICACY
- IMMUNE PROFILING
- NEW VACCINE DEVELOPMENT
- VACCINE ADJUVANTS
- DNA, RNA & SUBUNIT VACCINES
- VACCINE DELIVERY SYSTEMS
- VACCINES QA & QC
- VETERINARY VACCINES
- VACCINE DESIGN

VSBOSTON23 (EVENT SCHEDULE)

CONFERENCE VENUE

COMMONWEALTH BALLROOM
 BOSTON MARRIOTT NEWTON HOTEL
 2345 COMMONWEALTH AVENUE
 NEWTON, MA 02466, USA

MAY

22

MONDAY

- 08:00 **Inaugural Ceremony**
- 08:10 **Keynote Talks - I**
- 09:00 **Pre-Recorded Presentation**
- 09:30 Refreshment break - I
- 09:40 **Session Talks - I**
- 12:40 Lunch
- 13:30 **Session Talks - II**
- 16:30 Refreshment break - II
- 16:40 **Session Talks - II (Cont.)**
- 17:40 **Poster Presentation**

MAY

22

MONDAY

- 20:00 **GALA NETWORKING DINNER**



MAY

23

TUESDAY

- 08:00 **Inaugural Ceremony**
- 08:10 **Keynote Talks - II**
- 09:50 Refreshment break - I
- 10:00 **Session Talks - III**
- 13:30 Lunch
- 14:20 **Session Talks - IV**
- 16:20 Refreshment break - II
- 16:30 **Session Talks - IV (Cont.)**

MAY

24

WEDNESDAY

- 08:10 **Keynote Talks - III**
- 09:00 **Session Talks - V**
- 10:00 Refreshment break - I
- 10:10 **Session Talks - V (Cont.)**
- 12:40 Lunch

MAY
22 Monday

DAY 1 SCHEDULE

8:00-8:10 **INAUGURAL CEREMONY BY DON J. DIAMOND**

KEYNOTE TALKS - I

8:10-9:00 **DON J. DIAMOND**
Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, USA
Title: Development of CMV-MVA-Triplex vaccine for reduction of cytomegalovirus complication post-transplantation

9:00-9:30 **LUIGI BUONAGURO (PRE-RECORDED PRESENTATION)**
Director, Innovative Immunological Models Unit, National Cancer Institute - IRCCS "Pascale"
Title: Viral antigens as cancer vaccines

REFRESHMENT BREAK - I (10 MINS)

SESSION TALKS - I

CANCER VACCINES | NOVEL LIVE ATTENUATED VACCINES | HIV VACCINES

Session Chair: Pirouz Daftarian

Director of Scientific Engagement, Crown Bioscience & JSR Life Sciences, USA

9:40-10:10 **BRUNO FANT**
Chief Technical Officer, myNEO, Belgium
Title: Exploring and validating clinical validity of different sources of immunogenic targets for immunotherapy

10:10-10:40 **ELI GILBOA**
Dodson Professor for Microbiology & Immunology, University of Miami, USA
Title: Vaccination against a common set of neoantigens induced in tumors and pathogen infected cells

10:40-11:10 **ADAM E. SNOOK**
Associate Professor, Department of Pharmacology, Physiology, & Cancer Biology, Thomas Jefferson University, USA
Title: Adjuvant vaccines to prevent GI cancer recurrence

11:10-11:40 **JUDITH ALAMARES-SAPUAY**
Senior Scientist, Global Immunology, Vaccines R&D, Sanofi, USA
Title: Optimization and characterization of a live attenuated respiratory syncytial virus vaccine candidate

11:40-12:10 **PIROUZ DAFTARIAN**
Director of Scientific Engagement, Crown Bioscience, MBLI, and JSR Life Sciences, USA
Title: Today's metrics of immunogenicity of cancer vaccines

12:10-12:40

MARTIN MOORE

Founder & Chief Scientific Officer, Meissa Vaccines, USA

Title: Safety and immunogenicity of a live, attenuated RSV vaccine in RSV-naive children 6 to 36 months of age

LUNCH BREAK (50 MINS)

SESSION TALKS - II

DNA, RNA & SUBUNIT VACCINES | COVID-19 VACCINE R&D | NEW VACCINE DEVELOPMENT-I

Session Chair: Sarita K. Acharya

Principal Scientist, Global Biologics, United States Pharmacopeia, USA

13:30-14:00

SARITA K. ACHARYA

Principal Scientist, Global Biologics, United States Pharmacopeia, USA

Title: Ensuring quality and safety of mRNA vaccines today & tomorrow

14:00-14:30

KUN ZHOU

Project Lead, GeneLeap Biotech, USA

Title: A Novel mRNA-based therapeutic vaccine to target HPV16-associated cervical lesions

14:30-15:00

VIRA BITKO

Vice President, Head of Vaccine Therapeutics, RVAC Medicines, USA

Title: Development of RSV mRNA vaccine

15:00-15:30

DON J. DIAMOND

Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, USA representing GeoVax, USA

Title: Assessment of Geo-CM04S1 for prevention of COVID-19 in immunocompromised cell therapy patients; An open-label safety study

15:30-16:00

FENG XUAN

Co-founder, President & CTO, Spear Bio, USA

Title: A novel ultrasensitive cell-free SARS-CoV-2 neutralizing antibody assay for measuring humoral immune response of vaccine with high lab-to-lab consistency

16:00-16:30

URMI CHHEDA

Associate Scientist, GreenLight Biosciences, USA

Title: Stability of mRNA LNP

REFRESHMENT BREAK - II (10 MINS)

16:40-17:10

THORSTEN VOGEL

Director, Technology & External Innovation, Global Immunology, Research, Sanofi, USA

Title: Proof of concept of multivalent/octavalent vaccine platforms in naïve ferrets to deliver Influenza HA and NA antigens together for improved immunogenicity against NA compared to standard Influenza vaccines

17:10-17:40

MITHILA FERDOUS

Senior Scientist, Department of Global Immunology, Sanofi, USA

Title: Evaluation of novel influenza mRNA vaccine supplemented with neuraminidase to improve protection against disease in ferrets

POSTER PRESENTATION (30 MINS)

MAY
23 Tuesday

DAY 2 SCHEDULE

8:00-8:10

INAUGURAL SPEECH BY SABINE HAUCK

KEYNOTE TALKS - II

8:10-9:00

SABINE HAUCK

EVP Corporate Development, Leukocare AG, Germany

Title: Next generation in formulation development for vaccines

9:00-9:50

WILLIAM R. JACOBS JR.

Leo & Julia Forchheimer Chair, Microbiology and Immunology, Albert Einstein College of Medicine, USA

Title: Current progress towards a new tuberculosis vaccine

REFRESHMENT BREAK - I (10 MINS)

SESSION TALKS - III

IMMUNE PROFILING | VACCINE DESIGN | NEW VACCINE DEVELOPMENT-II

Session Chair: Kevin P. Killeen

Chief Scientific Officer, Matrivax, USA

10:00-10:30

AARON ESSER-KAHN

Associate Professor, Pritzker School of Molecular Engineering, University of Chicago, USA

Title: The challenge of making every vaccine safer and more effective: Engineering signal processing of innate immune cells

10:30-11:00

MAGDALENA TARY-LEHMANN

Chief Scientific Officer, Cellular Technology Limited, USA

Title: Immunogenicity assessment in support of gene therapy programs - use of ELISPOT

11:00-11:30

DE-CHU CHRISTOPHER TANG

Chief Executive Officer, VaxDome, USA

Title: Broad-spectrum vaccine-antiviral hybrid without constraints imposed by viral mutations

11:30-12:00

JOSEPH G. JOYCE

Distinguished Scientist, Vaccine Process R&D (VPRD), Merck, USA

Title: Development and clinical assessment of a novel 21-valent pneumococcal conjugate vaccine (V116)

12:00-12:30

VICTOR BRONSHTEIN

President & CSO, Universal Stabilization Technologies (Vitrilife), USA

Title: Vitrilife® technology platform for industrial production and mucosal delivery of thermostable vaccines and other biopharmaceuticals

12:30-13:00

MARK EMALFARB

President & CEO, Dyadic International, USA

Title: Transforming manufacturing & closing the technology gap between developed and developing countries

13:00-13:30

KEVIN P. KILLEEN

Chief Scientific Officer, Matrivax, USA

Title: MVX01: A global, serotype-independent, pneumococcal protein fusion vaccine candidate

LUNCH BREAK (50 MINS)

SESSION TALKS - IV

CLINICAL TRIALS | VACCINE DELIVERY SYSTEMS | BIOPROCESSING & MANUFACTURING

Session Chair: Shahin Gharakhanian

MD Consulting LLC, CIC: Cambridge Innovation Center, USA

14:20-14:50

ROBERT DILLMAN

Chief Medical Officer, AIVITA Biomedical, USA

Title: Clinical progress with personal dendritic cell vaccines for cancer and covid infection

14:50-15:20

VANESSA ELHARRAR

Vice President, Vaccines Business Strategy Lead, PPD, USA

Title: Key considerations for vaccine development in special populations (elderly, pregnant, immuno-compromised, pediatrics)

15:20-15:50

MICHAEL SUMNER

Chief Medical Officer, Inovio, USA

Title: Advancing DNA medicines: Clinical updates on Ebola and recurrent respiratory papillomatosis candidates

15:50-16:20

SHAHIN GHARAKHANIAN

MD Consulting LLC, CIC: Cambridge Innovation Center, USA

Title: P28GST, a therapeutic vaccine for the treatment of chronic inflammatory diseases. Data supporting clinical indication and case study

REFRESHMENT BREAK - II (10 MINS)

16:30-17:00

LYNDA TUSSEY

Chief Development Officer, Vaxess Technologies, USA

Title: Phase 1 clinical evaluation of VX-103: A sustained-release, patch-based influenza vaccine delivered on the MIMIX™ platform

17:00-17:30

JAMES Z. DENG

Associate Principal Scientist, Vaccine Analytical R&D, Merck, USA

Title: Analytical strategies for characterization of multi-valent pneumococcal conjugate vaccine

17:30-18:00

MIC MCGOLDRICK

Associate Director Global CMC Policy, Merck&Co., Inc. on behalf of IFPMA, USA

Title: Accelerating access to vaccines – Next steps beyond the pandemic

18:00-18:30

MATTHEW A. COLEMAN

Staff Scientist, Lawrence Livermore National Laboratory, USA

Title: Co-translational cell-free expression of Chlamydial membrane bound proteins for antigen discovery and application

MAY

24

Wednesday

DAY 3 SCHEDULE

KEYNOTE SESSION - III

8:10-9:00

ADRIAN V. S. HILL

Director, The Jenner Institute, University of Oxford, UK

Title: Phase 3 progress with a high efficacy malaria vaccine

SESSION TALKS - V

INFLUENZA & RESPIRATORY | BACTERIAL, TB & MALARIAL VACCINES | VETERINARY VACCINES
EMERGING & RE-EMERGING DISEASES

Session Chair: Trudy Morrison

Professor, University of Massachusetts Chan Medical School, USA

9:00-9:30

TRUDY MORRISON

Professor, University of Massachusetts Chan Medical School, USA

Title: The Respiratory syncytial virus G protein enhances the immune responses to the RSV F protein in an enveloped virus-like particle vaccine candidate

9:30-10:00

CHRISTOPHER P. LOCHER

Co-Founder & CEO, Versatope Therapeutics, USA

Title: Structure and function of a broad-strain influenza vaccine using nano-vesicles

REFRESHMENT BREAK - I (10 MINS)

10:10-10:40

JUN LIN

Professor of Infectious Disease, The University of Tennessee, USA

Title: Enterobactin-based immune intervention against Gram-negative pathogens

10:40-11:10

SELVAKUMAR SUBBIAN

Principal Investigator, Public Health Research Institute, New Jersey Medical School, Rutgers University, USA

Title: Immune response of BCG vaccination is shaped by the nature and infectious inoculum of pathogenic Mycobacterium tuberculosis

11:10-11:40

CHINNASWAMY JAGANNATH

Professor, Pathology & Genomic Medicine, Houston Methodist Research Institute & Weill Cornell Medical College, USA

Title: New generation adenoviral and mRNA-based tuberculosis vaccines

11:40-12:10

DEEPAK KAUSHAL

Professor, Senior Leadership Member of the SNPRC, Texas Biomedical Research Institute, USA

Title: Prevention of tuberculosis in a second species of nonhuman primates by an attenuated, stress-response deficient mutant of Mycobacterium tuberculosis

12:10-12:40

JOSEPH M. VINETZ

Professor of Medicine (Infectious Diseases), Yale University School of Medicine, USA

Title: Exploiting bacterial genomics to delineate mechanisms of pathogenesis, enabling vaccine development for an emerging/re-emerging zoonotic infectious disease

LUNCH BREAK (60 MINS)

POSTER-01

ANDREW J. RENNEKAMP

Medical Science Liaison, CSL Seqirus, USA

Title: Real world study of adjuvanted influenza vaccine in preventing cardio-respiratory related hospitalizations in the elderly during the 2019-2020 U.S. influenza season

POSTER-02

MARK EMALFARB

President & CEO, Dyadic International, USA

Title: Development of the thermophilic filamentous fungus Thermothelomyces heterothallica C1 into a prominent human and animal vaccines production platform

POSTER-03

ABEL E. VASQUEZ

Head Biotechnology Section. Public Health Institute of Chile, Universidad del Alba, Santiago, Chile.

Title: The surface immunogenic recombinant protein from *Streptococcus agalactiae* is a potential new vaccine adjuvant

POSTER-04

KAROLYNE WARNY

Senior Research Associate, Global Immunology, Sanofi, USA

Title: Preclinical benefit of recombinant NA addition to HA-based protein vaccine reduced disease severity in a ferret challenge model

Thank you
